AG-13958 (AG-013958), a VEGFR tyrosine kinase inhibitor, is in clinical development with ST administration for treatment of choroidal neovascularization associated with age–related macular degeneration (AMD).
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
AG-13958 (AG-013958), a VEGFR tyrosine kinase inhibitor, is in clinical development with ST administration for treatment of choroidal neovascularization associated with age–related macular degeneration (AMD).
[1] M.B. Kosa,et al.Investigative Ophthalmology & Visual Science. 2005;46: 5379.
没有评价数据